Headlines about Flex Pharma (NASDAQ:FLKS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flex Pharma earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Edited Transcript of FLKS earnings conference call or presentation 2-Aug-17 12:45pm GMT (finance.yahoo.com)
- Flex Pharma, Inc. (FLKS) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS (americanbankingnews.com)
- Investor Network: Flex Pharma, Inc. to Host Earnings Call (finance.yahoo.com)
- Flex Pharma Reports Second Quarter 2017 Financial Results (finance.yahoo.com)
- Flex Pharma reports 2Q loss (finance.yahoo.com)
FLKS has been the subject of a number of recent research reports. Jefferies Group LLC dropped their price objective on shares of Flex Pharma from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, May 4th. Zacks Investment Research cut shares of Flex Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $15.40.
Shares of Flex Pharma (NASDAQ:FLKS) traded down 1.75% during mid-day trading on Friday, reaching $3.92. 42,019 shares of the company were exchanged. The company’s 50 day moving average price is $3.89 and its 200 day moving average price is $3.96. Flex Pharma has a 12 month low of $3.01 and a 12 month high of $12.68. The firm’s market capitalization is $67.15 million.
Flex Pharma (NASDAQ:FLKS) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.12. Flex Pharma had a negative net margin of 2,624.17% and a negative return on equity of 73.02%. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.46 million. Equities analysts anticipate that Flex Pharma will post ($2.42) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Flex Pharma (FLKS) Receives News Sentiment Score of 0.19” was first posted by BBNS and is owned by of BBNS. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://baseballnewssource.com/markets/flex-pharma-flks-receiving-somewhat-favorable-press-coverage-accern-reports-updated-updated-updated/1180263.html.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc and related companies with our FREE daily email newsletter.